{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 794
        },
        "id": "7fYzrMBnSL7h",
        "outputId": "05f4881e-79ca-4055-9b4d-2697c2d896d4"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n",
            "[nltk_data] Downloading package vader_lexicon to /root/nltk_data...\n",
            "[nltk_data]   Package vader_lexicon is already up-to-date!\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                                             Article  \\\n",
              "0  Retailers, the makers of foods marketed for we...   \n",
              "1  Move over, Ozempic — there’s a new drug in tow...   \n",
              "2  Sept 14 (Reuters) - Bristol Myers Squibb (BMY....   \n",
              "3  Austin Wolcott was 18 years old and pretty sur...   \n",
              "4  Cancer, often referred to as the “emperor of a...   \n",
              "\n",
              "                                     Cleaned_Article  \n",
              "0  retailers makers foods marketed weight loss ty...  \n",
              "1  move ozempic — there’s new drug town eli lilly...  \n",
              "2  sept 14 reuters bristol myers squibb bmyn said...  \n",
              "3  austin wolcott 18 years old pretty sure wouldn...  \n",
              "4  cancer often referred “emperor maladies” unyie...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-14ecbc1f-8e29-45b8-8e88-b6a0212bacfe\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Article</th>\n",
              "      <th>Cleaned_Article</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Retailers, the makers of foods marketed for we...</td>\n",
              "      <td>retailers makers foods marketed weight loss ty...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Move over, Ozempic — there’s a new drug in tow...</td>\n",
              "      <td>move ozempic — there’s new drug town eli lilly...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Sept 14 (Reuters) - Bristol Myers Squibb (BMY....</td>\n",
              "      <td>sept 14 reuters bristol myers squibb bmyn said...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Austin Wolcott was 18 years old and pretty sur...</td>\n",
              "      <td>austin wolcott 18 years old pretty sure wouldn...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Cancer, often referred to as the “emperor of a...</td>\n",
              "      <td>cancer often referred “emperor maladies” unyie...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-14ecbc1f-8e29-45b8-8e88-b6a0212bacfe')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-14ecbc1f-8e29-45b8-8e88-b6a0212bacfe button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-14ecbc1f-8e29-45b8-8e88-b6a0212bacfe');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-b25e027c-91ed-4b8c-8ff3-d6752553d513\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b25e027c-91ed-4b8c-8ff3-d6752553d513')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-b25e027c-91ed-4b8c-8ff3-d6752553d513 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"combined_df\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"Article\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Move over, Ozempic \\u2014 there\\u2019s a new drug in town.\\n\\nEli Lilly\\u2019s Zepbound, with the active ingredient tirzepatide, has been approved by the Food and Drug Administration for use by obese or overweight adults who have at least one weight-related health complication, like Type 2 diabetes, high blood pressure or high cholesterol.\\n\\nTirzepatide, sold as Mounjaro, has already been approved for treating type 2 diabetes since May 2022, but now, patients can be prescribed the drug for chronic weight management.\\n\\n\\u201cObesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes,\\u201d Dr. John Sharretts, the director of the Division of Diabetes, Lipid Disorders, and Obesity for the FDA\\u2019s Center for Drug Evaluation and Research, said in a statement.\\n\\n\\u201cIn light of increasing rates of both obesity and overweight in the United States, today\\u2019s approval addresses an unmet medical need.\\u201d\\n\\nApproximately 70% of Americans are overweight or obese, according to the FDA, and a worrying report published by the World Obesity Federation this year projected that more than half of the world\\u2019s population could be overweight or obese by 2035.\\n\\nHowever, the FDA reports that dropping only 5% to 10% of overall body weight can lower the risk of developing heart disease as a result \\u2014 cue weight management drugs, which can help people lose stubborn pounds when diet and exercise alone fail.\\n\\n\\u201cUnfortunately, despite scientific evidence to the contrary, obesity is often seen as a lifestyle choice \\u2013 something that people should manage themselves,\\u201d Dr. Leonard Glass, the senior vice president global medical affairs at Lilly Diabetes and Obesity, said in a statement.\\n\\n\\u201cLilly is aiming to eliminate misperceptions about this disease and transform how it can be managed.\\u201d\\n\\nZepbound, which was approved Wednesday, has been shown to be an effective chronic weight management drug in combination with lifestyle changes like diet and exercise by activating the receptors for two hormones \\u2014 glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) \\u2014 to suppress appetite, thereby curbing food intake.\\n\\nSide effects of the weekly injectable include nausea, vomiting, abdominal discomfort or pain, fatigue, diarrhea, constipation burping, hair loss, acid reflux and allergic reactions.\\n\\nIn trials, the drug caused thyroid C-cell tumors in rodents, although it is unknown whether Zepbound can result in the same cancer in humans.\\n\\nAccording to the drug\\u2019s manufacturer, Zepbound is expected to be available to Americans by the end of the year for a list price of approximately $1,059, which Eli Lilly estimates is 20% less than rival semaglutide, otherwise known as Novo Nordisk\\u2019s Ozempic or Wegovy, which costs a staggering $1,300.\\n\\nBut as the demand for a weight loss cure-all soars has led to a market of dangerous counterfeit dupes, which have landed desperate users in the hospital.\\n\\nAnd, despite the pressure for more medication access, \\u201cit does not improve or change insurance coverage,\\u201d which has been limited, explained Dr. Angela Fitch, the chief medical officer at weight-inclusive healthcare company knownwell.\\n\\n\\u201cIt remains a problem that obesity is treated as a carve out condition instead of a standard benefit, despite the fact that it is a chronic condition,\\u201d she told The Post in a statement.\\n\\n\\u201cWe\\u2019re hopeful that with continued advocacy, advancement in science, and data, we will continue to see improved access to this life-changing medication.\\u201d\",\n          \"Cancer, often referred to as the \\u201cemperor of all maladies,\\u201d is an unyielding adversary that presents formidable challenges to global health. It is a complex amalgamation of diseases, each with its own unique characteristics, making its treatment a continuous, arduous battle for both healthcare professionals and patients. In this ever-evolving landscape of cancer therapeutics, one name that is carving out a unique space with innovative solutions is CytoMed Therapeutics.\\n\\nEquipped with a novel, disruptive approach that blends advanced cellular science with cutting-edge biotechnology, CytoMed is championing a revolution, aiming to transform the battlefield of cancer treatment. Their mission is not just about finding effective solutions, but also making those solutions accessible and affordable for all, thereby addressing one of the most significant barriers in cancer care - prohibitive costs. The journey of CytoMed encapsulates a determined stride towards breaking barriers, changing narratives, and bringing hope to millions affected by cancer globally.\\n\\nCancer, an umbrella term for a multitude of diseases characterized by the uncontrolled growth and spread of cells, stands as a testament to biological complexity. This conglomerate of diseases, each with unique genetic mutations, cellular interactions, and responses to external factors, puts forth a staggering level of intricacy, making it a considerable challenge to formulate and execute effective treatments. This complexity is not only confined to the biological dimension, but it also extends to the socio-economic aspects of cancer care.\\n\\nThe diverse range of cancer subtypes, each with distinct biological characteristics, necessitates the development of a plethora of therapies, each tailored to target a specific cancer type or stage. This approach, while potentially effective, inevitably inflates the cost of research, development, and production of these therapies, thereby driving up the overall cost of cancer treatment.\\n\\nAdding to the equation, cancer\\u2019s relentless nature often demands long-term, intensive treatments, further escalating the financial burden on patients and healthcare systems. The financial toxicity associated with cancer treatment is so significant that it often poses an insurmountable barrier to access, making potentially lifesaving treatments unattainable for many patients.\\n\\nIn this context, Dr. Wee Kiat Tan, Chief Operating Officer of CytoMed Therapeutics, underlines a profound truth, saying, \\\"You could have the best solution to a disease or treatment, but if it is not affordable, how are you going to?\\\" This sentiment not only highlights the inherent challenge in cancer treatment but also brings to the fore the core philosophy of CytoMed Therapeutics \\u2013 to develop not just effective, but also affordable solutions for cancer. In the ongoing war against cancer, Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a revolutionary ally. By leveraging the body's own immune system to fight cancer, CAR-T therapy has unlocked new avenues of hope for countless patients. This groundbreaking treatment modality involves genetically modifying a patient's T cells to recognize and destroy cancer cells, effectively turning the immune system into a potent, precise weapon against the disease.\\n\\nCAR-T therapy, which represents a personalized approach to cancer treatment, has been particularly effective against blood cancers like leukemia and lymphoma. The results from various clinical trials have been compelling, with some patients achieving complete remission, a term rarely associated with advanced-stage cancer.\\n\\nHowever, despite its transformative potential, CAR-T therapy has its own set of challenges. Firstly, the cost associated with this therapy is exceptionally high. This is largely because each CAR-T therapy is custom-made for each patient, involving a complex process of extraction, genetic modification, and reinfusion of T cells. This high degree of customization requires specialized labs, sophisticated technologies, and skilled personnel, all of which contribute to the overall cost. The patient-specific nature of CAR-T therapy means it cannot be mass-produced or stored for future use. This raises scalability issues, particularly when attempting to treat a large number of patients. In addition, the time taken from cell extraction to reinfusion can span several weeks, a duration during which the patient's condition can potentially deteriorate.\\n\\nIn light of the hurdles associated with traditional CAR-T therapy, CytoMed Therapeutics is offering a potentially game-changing alternative. The biotechnology company has pioneered a \\u201cone product, many patients\\u201d approach, a strategy that eliminates the need for patient-specific customization, thereby addressing some of the critical limitations of traditional CAR-T therapy.\\n\\nAt the core of CytoMed's strategy are Gamma Delta T cells, a subgroup of T cells derived from healthy donors. Gamma Delta T cells have long been an underappreciated part of the immune system, but recent research has begun to shed light on their potential. Unlike other T cells, Gamma Delta T cells can recognize a wide array of cancers without the need for complex genetic modification, which has conventionally been a prerequisite for CAR-T therapies.\\n\\nThe universal applicability of these cells allows CytoMed to create an \\u201coff-the-shelf\\\" product, a significant departure from the traditional CAR-T model. By eliminating the need for patient-specific customization, CytoMed's approach can reduce both the cost and logistical complexity associated with the therapy. In essence, the company is working to democratize access to this advanced cancer therapy, making it more accessible to a broader patient population.\\n\\nBy allowing for large-scale production of the therapy, CytoMed's model stands to significantly reduce the costs associated with CAR-T treatment. It could potentially transform CAR-T therapy from a high-cost, low-volume treatment into a more affordable, high-volume option, a shift that could revolutionize cancer treatment.\\n\\nThis \\u201cone product, many patients\\u201d paradigm, if successfully implemented, could mark a significant stride in the evolution of CAR-T therapy. By making a potent form of immunotherapy more universally applicable, CytoMed's approach could help to bring the promise of CAR-T therapy to a larger patient population. This is a critical step forward in making cancer treatment more equitable, affordable, and effective.\\n\\nCytoMed's relentless drive for innovation continues to break new ground in CAR-T therapy. Ongoing research and potential advancements, such as enhancing the efficiency of Gamma Delta T cell extraction and refining their precision targeting capabilities, are actively being pursued.\\n\\nThe vision of a future where high-quality cancer therapy is not a privilege but a standard accessible to all grows ever closer with CytoMed's ongoing efforts. Dr. Tan passionately sums up this aspiration: \\\"You have a good solution, but you have to make it affordable.\\\"\",\n          \"Sept 14 (Reuters) - Bristol Myers Squibb (BMY.N) said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with increasing generic competition for two of its top-selling drugs.\\n\\nThe drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies that target immune system disorders and different types of cancer.\\n\\nThe New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition.\\n\\nBristol and partner Pfizer's (PFE.N) blood thinner Eliquis was also on the list of 10 drugs that will be subject to the first-ever price negotiations by the U.S. Medicare health program.\\n\\nThe company recently received regulatory approval for a new cell therapy manufacturing facility in Devens, Massachusetts and Bristol said it will continue expanding its manufacturing capacity.\\n\\nBristol, which already has two approved cell therapies in the U.S., Breyanzi and Abecma, targeting different blood cancer indications, said it plans to continue development for treatment of other diseases such as lupus erythematosus and multiple sclerosis.\\n\\nThe drugmaker is hosting an R&D day on Thursday, where executives are expected to provide details of the company's research strategy.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Cleaned_Article\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"move ozempic \\u2014 there\\u2019s new drug town eli lilly\\u2019s zepbound active ingredient tirzepatide approved food drug administration use obese overweight adults least one weightrelated health complication like type 2 diabetes high blood pressure high cholesterol tirzepatide sold mounjaro already approved treating type 2 diabetes since may 2022 patients prescribed drug chronic weight management \\u201cobesity overweight serious conditions associated leading causes death heart disease stroke diabetes\\u201d dr john sharretts director division diabetes lipid disorders obesity fda\\u2019s center drug evaluation research said statement \\u201cin light increasing rates obesity overweight united states today\\u2019s approval addresses unmet medical need\\u201d approximately 70 americans overweight obese according fda worrying report published world obesity federation year projected half world\\u2019s population could overweight obese 2035 however fda reports dropping 5 10 overall body weight lower risk developing heart disease result \\u2014 cue weight management drugs help people lose stubborn pounds diet exercise alone fail \\u201cunfortunately despite scientific evidence contrary obesity often seen lifestyle choice \\u2013 something people manage themselves\\u201d dr leonard glass senior vice president global medical affairs lilly diabetes obesity said statement \\u201clilly aiming eliminate misperceptions disease transform managed\\u201d zepbound approved wednesday shown effective chronic weight management drug combination lifestyle changes like diet exercise activating receptors two hormones \\u2014 glucagonlike peptide1 glp1 glucosedependent insulinotropic polypeptide gip \\u2014 suppress appetite thereby curbing food intake side effects weekly injectable include nausea vomiting abdominal discomfort pain fatigue diarrhea constipation burping hair loss acid reflux allergic reactions trials drug caused thyroid ccell tumors rodents although unknown whether zepbound result cancer humans according drug\\u2019s manufacturer zepbound expected available americans end year list price approximately 1059 eli lilly estimates 20 less rival semaglutide otherwise known novo nordisk\\u2019s ozempic wegovy costs staggering 1300 demand weight loss cureall soars led market dangerous counterfeit dupes landed desperate users hospital despite pressure medication access \\u201cit improve change insurance coverage\\u201d limited explained dr angela fitch chief medical officer weightinclusive healthcare company knownwell \\u201cit remains problem obesity treated carve condition instead standard benefit despite fact chronic condition\\u201d told post statement \\u201cwe\\u2019re hopeful continued advocacy advancement science data continue see improved access lifechanging medication\\u201d\",\n          \"cancer often referred \\u201cemperor maladies\\u201d unyielding adversary presents formidable challenges global health complex amalgamation diseases unique characteristics making treatment continuous arduous battle healthcare professionals patients everevolving landscape cancer therapeutics one name carving unique space innovative solutions cytomed therapeutics equipped novel disruptive approach blends advanced cellular science cuttingedge biotechnology cytomed championing revolution aiming transform battlefield cancer treatment mission finding effective solutions also making solutions accessible affordable thereby addressing one significant barriers cancer care prohibitive costs journey cytomed encapsulates determined stride towards breaking barriers changing narratives bringing hope millions affected cancer globally cancer umbrella term multitude diseases characterized uncontrolled growth spread cells stands testament biological complexity conglomerate diseases unique genetic mutations cellular interactions responses external factors puts forth staggering level intricacy making considerable challenge formulate execute effective treatments complexity confined biological dimension also extends socioeconomic aspects cancer care diverse range cancer subtypes distinct biological characteristics necessitates development plethora therapies tailored target specific cancer type stage approach potentially effective inevitably inflates cost research development production therapies thereby driving overall cost cancer treatment adding equation cancer\\u2019s relentless nature often demands longterm intensive treatments escalating financial burden patients healthcare systems financial toxicity associated cancer treatment significant often poses insurmountable barrier access making potentially lifesaving treatments unattainable many patients context dr wee kiat tan chief operating officer cytomed therapeutics underlines profound truth saying could best solution disease treatment affordable going sentiment highlights inherent challenge cancer treatment also brings fore core philosophy cytomed therapeutics \\u2013 develop effective also affordable solutions cancer ongoing war cancer chimeric antigen receptor tcell cart therapy emerged revolutionary ally leveraging bodys immune system fight cancer cart therapy unlocked new avenues hope countless patients groundbreaking treatment modality involves genetically modifying patients cells recognize destroy cancer cells effectively turning immune system potent precise weapon disease cart therapy represents personalized approach cancer treatment particularly effective blood cancers like leukemia lymphoma results various clinical trials compelling patients achieving complete remission term rarely associated advancedstage cancer however despite transformative potential cart therapy set challenges firstly cost associated therapy exceptionally high largely cart therapy custommade patient involving complex process extraction genetic modification reinfusion cells high degree customization requires specialized labs sophisticated technologies skilled personnel contribute overall cost patientspecific nature cart therapy means cannot massproduced stored future use raises scalability issues particularly attempting treat large number patients addition time taken cell extraction reinfusion span several weeks duration patients condition potentially deteriorate light hurdles associated traditional cart therapy cytomed therapeutics offering potentially gamechanging alternative biotechnology company pioneered \\u201cone product many patients\\u201d approach strategy eliminates need patientspecific customization thereby addressing critical limitations traditional cart therapy core cytomeds strategy gamma delta cells subgroup cells derived healthy donors gamma delta cells long underappreciated part immune system recent research begun shed light potential unlike cells gamma delta cells recognize wide array cancers without need complex genetic modification conventionally prerequisite cart therapies universal applicability cells allows cytomed create \\u201cofftheshelf product significant departure traditional cart model eliminating need patientspecific customization cytomeds approach reduce cost logistical complexity associated therapy essence company working democratize access advanced cancer therapy making accessible broader patient population allowing largescale production therapy cytomeds model stands significantly reduce costs associated cart treatment could potentially transform cart therapy highcost lowvolume treatment affordable highvolume option shift could revolutionize cancer treatment \\u201cone product many patients\\u201d paradigm successfully implemented could mark significant stride evolution cart therapy making potent form immunotherapy universally applicable cytomeds approach could help bring promise cart therapy larger patient population critical step forward making cancer treatment equitable affordable effective cytomeds relentless drive innovation continues break new ground cart therapy ongoing research potential advancements enhancing efficiency gamma delta cell extraction refining precision targeting capabilities actively pursued vision future highquality cancer therapy privilege standard accessible grows ever closer cytomeds ongoing efforts dr tan passionately sums aspiration good solution make affordable\",\n          \"sept 14 reuters bristol myers squibb bmyn said thursday plans double number treatments testing clinical trials focus cell therapies next 18 months contends increasing generic competition two topselling drugs drugmaker currently six candidates trials advance six research pipeline including three cell therapies target immune system disorders different types cancer new yorkbased company pressured declining demand two top drugs blood cancer treatment revlimid blood thinner eliquis face generic competition bristol partner pfizers pfen blood thinner eliquis also list 10 drugs subject firstever price negotiations us medicare health program company recently received regulatory approval new cell therapy manufacturing facility devens massachusetts bristol said continue expanding manufacturing capacity bristol already two approved cell therapies us breyanzi abecma targeting different blood cancer indications said plans continue development treatment diseases lupus erythematosus multiple sclerosis drugmaker hosting rd day thursday executives expected provide details companys research strategy\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Missing values before handling:\n",
            "Article            5\n",
            "Cleaned_Article    0\n",
            "Mood_Rating        0\n",
            "dtype: int64\n",
            "Missing values after handling:\n",
            "Article            5\n",
            "Cleaned_Article    0\n",
            "Mood_Rating        0\n",
            "dtype: int64\n",
            "Classification Report:\n",
            "              precision    recall  f1-score   support\n",
            "\n",
            "    Positive       1.00      1.00      1.00         6\n",
            "\n",
            "    accuracy                           1.00         6\n",
            "   macro avg       1.00      1.00      1.00         6\n",
            "weighted avg       1.00      1.00      1.00         6\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                                     Cleaned_Article  \\\n",
              "0  retailers makers foods marketed weight loss ty...   \n",
              "1  move ozempic — there’s new drug town eli lilly...   \n",
              "2  sept 14 reuters bristol myers squibb bmyn said...   \n",
              "3  austin wolcott 18 years old pretty sure wouldn...   \n",
              "4  cancer often referred “emperor maladies” unyie...   \n",
              "\n",
              "                                     Aspect_Analysis  \n",
              "0           {'cost': 'Positive', 'plan': 'Positive'}  \n",
              "1                               {'cost': 'Negative'}  \n",
              "2                               {'plan': 'Negative'}  \n",
              "3  {'innovation': 'Negative', 'cost': 'Negative',...  \n",
              "4     {'innovation': 'Negative', 'cost': 'Negative'}  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-15ccf425-06cb-47f0-a7b8-8bbb66339352\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Cleaned_Article</th>\n",
              "      <th>Aspect_Analysis</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>retailers makers foods marketed weight loss ty...</td>\n",
              "      <td>{'cost': 'Positive', 'plan': 'Positive'}</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>move ozempic — there’s new drug town eli lilly...</td>\n",
              "      <td>{'cost': 'Negative'}</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>sept 14 reuters bristol myers squibb bmyn said...</td>\n",
              "      <td>{'plan': 'Negative'}</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>austin wolcott 18 years old pretty sure wouldn...</td>\n",
              "      <td>{'innovation': 'Negative', 'cost': 'Negative',...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>cancer often referred “emperor maladies” unyie...</td>\n",
              "      <td>{'innovation': 'Negative', 'cost': 'Negative'}</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-15ccf425-06cb-47f0-a7b8-8bbb66339352')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-15ccf425-06cb-47f0-a7b8-8bbb66339352 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-15ccf425-06cb-47f0-a7b8-8bbb66339352');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-b0d1084c-c163-4428-93fa-743b4383673f\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b0d1084c-c163-4428-93fa-743b4383673f')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-b0d1084c-c163-4428-93fa-743b4383673f button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"combined_df\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"Cleaned_Article\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"move ozempic \\u2014 there\\u2019s new drug town eli lilly\\u2019s zepbound active ingredient tirzepatide approved food drug administration use obese overweight adults least one weightrelated health complication like type 2 diabetes high blood pressure high cholesterol tirzepatide sold mounjaro already approved treating type 2 diabetes since may 2022 patients prescribed drug chronic weight management \\u201cobesity overweight serious conditions associated leading causes death heart disease stroke diabetes\\u201d dr john sharretts director division diabetes lipid disorders obesity fda\\u2019s center drug evaluation research said statement \\u201cin light increasing rates obesity overweight united states today\\u2019s approval addresses unmet medical need\\u201d approximately 70 americans overweight obese according fda worrying report published world obesity federation year projected half world\\u2019s population could overweight obese 2035 however fda reports dropping 5 10 overall body weight lower risk developing heart disease result \\u2014 cue weight management drugs help people lose stubborn pounds diet exercise alone fail \\u201cunfortunately despite scientific evidence contrary obesity often seen lifestyle choice \\u2013 something people manage themselves\\u201d dr leonard glass senior vice president global medical affairs lilly diabetes obesity said statement \\u201clilly aiming eliminate misperceptions disease transform managed\\u201d zepbound approved wednesday shown effective chronic weight management drug combination lifestyle changes like diet exercise activating receptors two hormones \\u2014 glucagonlike peptide1 glp1 glucosedependent insulinotropic polypeptide gip \\u2014 suppress appetite thereby curbing food intake side effects weekly injectable include nausea vomiting abdominal discomfort pain fatigue diarrhea constipation burping hair loss acid reflux allergic reactions trials drug caused thyroid ccell tumors rodents although unknown whether zepbound result cancer humans according drug\\u2019s manufacturer zepbound expected available americans end year list price approximately 1059 eli lilly estimates 20 less rival semaglutide otherwise known novo nordisk\\u2019s ozempic wegovy costs staggering 1300 demand weight loss cureall soars led market dangerous counterfeit dupes landed desperate users hospital despite pressure medication access \\u201cit improve change insurance coverage\\u201d limited explained dr angela fitch chief medical officer weightinclusive healthcare company knownwell \\u201cit remains problem obesity treated carve condition instead standard benefit despite fact chronic condition\\u201d told post statement \\u201cwe\\u2019re hopeful continued advocacy advancement science data continue see improved access lifechanging medication\\u201d\",\n          \"cancer often referred \\u201cemperor maladies\\u201d unyielding adversary presents formidable challenges global health complex amalgamation diseases unique characteristics making treatment continuous arduous battle healthcare professionals patients everevolving landscape cancer therapeutics one name carving unique space innovative solutions cytomed therapeutics equipped novel disruptive approach blends advanced cellular science cuttingedge biotechnology cytomed championing revolution aiming transform battlefield cancer treatment mission finding effective solutions also making solutions accessible affordable thereby addressing one significant barriers cancer care prohibitive costs journey cytomed encapsulates determined stride towards breaking barriers changing narratives bringing hope millions affected cancer globally cancer umbrella term multitude diseases characterized uncontrolled growth spread cells stands testament biological complexity conglomerate diseases unique genetic mutations cellular interactions responses external factors puts forth staggering level intricacy making considerable challenge formulate execute effective treatments complexity confined biological dimension also extends socioeconomic aspects cancer care diverse range cancer subtypes distinct biological characteristics necessitates development plethora therapies tailored target specific cancer type stage approach potentially effective inevitably inflates cost research development production therapies thereby driving overall cost cancer treatment adding equation cancer\\u2019s relentless nature often demands longterm intensive treatments escalating financial burden patients healthcare systems financial toxicity associated cancer treatment significant often poses insurmountable barrier access making potentially lifesaving treatments unattainable many patients context dr wee kiat tan chief operating officer cytomed therapeutics underlines profound truth saying could best solution disease treatment affordable going sentiment highlights inherent challenge cancer treatment also brings fore core philosophy cytomed therapeutics \\u2013 develop effective also affordable solutions cancer ongoing war cancer chimeric antigen receptor tcell cart therapy emerged revolutionary ally leveraging bodys immune system fight cancer cart therapy unlocked new avenues hope countless patients groundbreaking treatment modality involves genetically modifying patients cells recognize destroy cancer cells effectively turning immune system potent precise weapon disease cart therapy represents personalized approach cancer treatment particularly effective blood cancers like leukemia lymphoma results various clinical trials compelling patients achieving complete remission term rarely associated advancedstage cancer however despite transformative potential cart therapy set challenges firstly cost associated therapy exceptionally high largely cart therapy custommade patient involving complex process extraction genetic modification reinfusion cells high degree customization requires specialized labs sophisticated technologies skilled personnel contribute overall cost patientspecific nature cart therapy means cannot massproduced stored future use raises scalability issues particularly attempting treat large number patients addition time taken cell extraction reinfusion span several weeks duration patients condition potentially deteriorate light hurdles associated traditional cart therapy cytomed therapeutics offering potentially gamechanging alternative biotechnology company pioneered \\u201cone product many patients\\u201d approach strategy eliminates need patientspecific customization thereby addressing critical limitations traditional cart therapy core cytomeds strategy gamma delta cells subgroup cells derived healthy donors gamma delta cells long underappreciated part immune system recent research begun shed light potential unlike cells gamma delta cells recognize wide array cancers without need complex genetic modification conventionally prerequisite cart therapies universal applicability cells allows cytomed create \\u201cofftheshelf product significant departure traditional cart model eliminating need patientspecific customization cytomeds approach reduce cost logistical complexity associated therapy essence company working democratize access advanced cancer therapy making accessible broader patient population allowing largescale production therapy cytomeds model stands significantly reduce costs associated cart treatment could potentially transform cart therapy highcost lowvolume treatment affordable highvolume option shift could revolutionize cancer treatment \\u201cone product many patients\\u201d paradigm successfully implemented could mark significant stride evolution cart therapy making potent form immunotherapy universally applicable cytomeds approach could help bring promise cart therapy larger patient population critical step forward making cancer treatment equitable affordable effective cytomeds relentless drive innovation continues break new ground cart therapy ongoing research potential advancements enhancing efficiency gamma delta cell extraction refining precision targeting capabilities actively pursued vision future highquality cancer therapy privilege standard accessible grows ever closer cytomeds ongoing efforts dr tan passionately sums aspiration good solution make affordable\",\n          \"sept 14 reuters bristol myers squibb bmyn said thursday plans double number treatments testing clinical trials focus cell therapies next 18 months contends increasing generic competition two topselling drugs drugmaker currently six candidates trials advance six research pipeline including three cell therapies target immune system disorders different types cancer new yorkbased company pressured declining demand two top drugs blood cancer treatment revlimid blood thinner eliquis face generic competition bristol partner pfizers pfen blood thinner eliquis also list 10 drugs subject firstever price negotiations us medicare health program company recently received regulatory approval new cell therapy manufacturing facility devens massachusetts bristol said continue expanding manufacturing capacity bristol already two approved cell therapies us breyanzi abecma targeting different blood cancer indications said plans continue development treatment diseases lupus erythematosus multiple sclerosis drugmaker hosting rd day thursday executives expected provide details companys research strategy\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Aspect_Analysis\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        }
      ],
      "source": [
        "import pandas as pd\n",
        "import string\n",
        "import nltk\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.sentiment import SentimentIntensityAnalyzer\n",
        "from collections import Counter\n",
        "from nltk.sentiment import SentimentIntensityAnalyzer\n",
        "from sklearn.model_selection import train_test_split\n",
        "from sklearn.feature_extraction.text import TfidfVectorizer\n",
        "from sklearn.linear_model import LogisticRegression\n",
        "from sklearn.metrics import accuracy_score, classification_report\n",
        "nltk.download('stopwords')\n",
        "nltk.download('vader_lexicon')\n",
        "\n",
        "# Load the Excel file\n",
        "file_path = '/content/Assignment.xlsx'\n",
        "xlsx = pd.ExcelFile(file_path)\n",
        "\n",
        "# Display sheet names\n",
        "sheet_names = xlsx.sheet_names\n",
        "sheet_names\n",
        "\n",
        "# Load the data from the \"assignment\" sheet\n",
        "assignment_df = pd.read_excel(file_path, sheet_name='Sheet1')\n",
        "\n",
        "# Display the first few rows of the dataframe\n",
        "assignment_df.head()\n",
        "\n",
        "def clean_article(text):\n",
        "    text = text.lower()\n",
        "    text = text.translate(str.maketrans('', '', string.punctuation))\n",
        "    stop_words = set(stopwords.words('english'))\n",
        "    text = ' '.join(word for word in text.split() if word not in stop_words)\n",
        "    return text\n",
        "\n",
        "assignment_df['Cleaned_Article'] = assignment_df['Article'].apply(clean_article)\n",
        "display(assignment_df[['Article', 'Cleaned_Article']].head())\n",
        "\n",
        "\n",
        "# Initialize the sentiment intensity analyzer\n",
        "sia = SentimentIntensityAnalyzer()\n",
        "\n",
        "def check_mood(text):\n",
        "    # Get the polarity scores\n",
        "    scores = sia.polarity_scores(text)\n",
        "    # Determine the mood based on the compound score\n",
        "    if scores['compound'] >= 0.05:\n",
        "        return 'Positive'\n",
        "    elif scores['compound'] <= -0.05:\n",
        "        return 'Negative'\n",
        "    else:\n",
        "        return 'Neutral'\n",
        "\n",
        "# Apply the mood check function to the cleaned articles\n",
        "assignment_df['Mood_Rating'] = assignment_df['Cleaned_Article'].apply(check_mood)\n",
        "assignment_df[['Cleaned_Article', 'Mood_Rating']].head()\n",
        "\n",
        "# Using a sample dataset for sentiment labels (you need to have a labeled dataset for supervised learning)\n",
        "sample_data = {\n",
        "    'Cleaned_Article': [\n",
        "        'Researchers find new cancer treatment big step forward',\n",
        "        'City council talks new park many residents attend',\n",
        "        'Scientists develop new solar panel more efficient fight climate change',\n",
        "        'Economy struggling many people losing jobs worrying trend',\n",
        "        'New report details latest scientific findings climate change report informative well written'\n",
        "    ],\n",
        "    'Mood_Rating': ['Positive', 'Neutral', 'Positive', 'Negative', 'Neutral']\n",
        "}\n",
        "sample_df = pd.DataFrame(sample_data)\n",
        "\n",
        "# Combine sample data with the assignment data (only for demonstration purposes)\n",
        "combined_df = pd.concat([assignment_df, sample_df], ignore_index=True)\n",
        "\n",
        "# Check for missing values\n",
        "print(\"Missing values before handling:\")\n",
        "print(combined_df.isnull().sum())\n",
        "\n",
        "# Drop rows with missing values\n",
        "combined_df.dropna(subset=['Cleaned_Article', 'Mood_Rating'], inplace=True)\n",
        "\n",
        "# Check for missing values again\n",
        "print(\"Missing values after handling:\")\n",
        "print(combined_df.isnull().sum())\n",
        "\n",
        "vectorizer = TfidfVectorizer()\n",
        "X = vectorizer.fit_transform(combined_df['Cleaned_Article'])\n",
        "y = combined_df['Mood_Rating']\n",
        "\n",
        "\n",
        "X_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.2, random_state=42)\n",
        "\n",
        "\n",
        "model = LogisticRegression()\n",
        "model.fit(X_train, y_train)\n",
        "\n",
        "\n",
        "y_pred = model.predict(X_test)\n",
        "accuracy = accuracy_score(y_test, y_pred)\n",
        "print(\"Classification Report:\")\n",
        "print(classification_report(y_test, y_pred))\n",
        "\n",
        "def aspect_analysis(text, aspects):\n",
        "    aspect_sentiments = {}\n",
        "    for aspect in aspects:\n",
        "        aspect_text = ' '.join([sentence for sentence in text.split('.') if aspect in sentence])\n",
        "        if aspect_text:\n",
        "            aspect_vector = vectorizer.transform([aspect_text])\n",
        "            aspect_sentiment = model.predict(aspect_vector)\n",
        "            aspect_sentiments[aspect] = aspect_sentiment[0]\n",
        "    return aspect_sentiments\n",
        "\n",
        "aspects = ['innovation', 'cost', 'plan', 'traffic', 'impact']\n",
        "combined_df['Aspect_Analysis'] = combined_df['Cleaned_Article'].apply(lambda x: aspect_analysis(x, aspects))\n",
        "display(combined_df[['Cleaned_Article', 'Aspect_Analysis']].head())\n",
        "\n",
        "output_path = 'assignment_processed_with_aspect_analysis.xlsx'\n",
        "combined_df.to_excel(output_path, index=False)\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "gz67VmDQShBa"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}